FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 883 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Liquid Biopsy Detects Brain Cancer and Early-Stage Kidney Cancer July 23, 2020 News digest – dinosaur bone cancer, YouTube junk food ad ban... August 8, 2020 Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in... June 30, 2026 Workout Wednesday – Leg Stretches Part 1 July 8, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Capmatinib For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored Mortality From PSA-Detected Localised Prostate Cancer Remains Very Low Regardless of... How Financial Toxicity Can Impact Cancer Caregivers and Where to Find...
